Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus MOXEZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus MOXEZA.
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER vs MOXEZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination.
400 mg intravenously every 8 to 12 hours for most infections; 400 mg every 8 hours for severe/complicated infections.
400 mg orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life is 3.5-5 hours in patients with normal renal function. Clinically, this supports twice-daily dosing. In severe renal impairment (CrCl <30 mL/min), half-life may extend to 6-9 hours, requiring dose adjustment.
Terminal half-life: 12 hours; allows once-daily dosing
Renal excretion accounts for approximately 50-70% of the dose as unchanged drug via glomerular filtration and tubular secretion; fecal excretion accounts for 15-25%, with about 20% as unchanged drug; biliary excretion contributes minimally (<5%).
Renal: 70% unchanged; biliary/fecal: 20%; metabolized: 10%
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic